Massachusetts Patent of the Month – June 2021

Nucleic acid-based technologies are used in a variety of therapeutic applications. The delivery of nucleic acids has traditionally been done through specific formulas that protect them from degradation in vivo. Translate Bio, Inc. has designed an improved delivery system that utilizes lipid nanoparticles. Their system incorporates three lipid components that result in high RNA encapsulation efficiency and accurate delivery.

Their system specifically uses a sterol-based cationic lipid, helper lipid, and PEG-modified lipid. Cationic lipids have been used before, as they promote interaction with the mRNA during encapsulation which helps to capture and protect the mRNA. The sterol-based cationic lipids have proven even more efficient at delivering this mRNA than the traditional titratable cationic lipids used. The combination of these three lipids results in the highest efficacy, creating an mRNA therapy with less mRNA needed, less side effects, and better results.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts